Page last updated: 2024-12-10

thiamylal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thiamylal: A barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, p919) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

thiamylal : A member of the class of barbiturates that is 2-thioxodihydropyrimidine-4,6(1H,5H)-dione substituted by a pentan-2-yl and prop-2-en-1-yl group at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3032285
CHEMBL ID440
CHEBI ID9536
SCHEMBL ID548050
SCHEMBL ID12998413
MeSH IDM0021329

Synonyms (63)

Synonym
BRD-A23970436-236-02-6
nsc120815
barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-
thioseconal
nsc-120815
4,5h)-pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-
surital
4,6(1h,5h)-pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-
DIVK1C_000990
KBIO1_000990
5-allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1h,5h)-pyrimidinedione
5-allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1h,5h)-dione
dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1h,5h)-pyrimidinedione
5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidenedihydropyrimidine-4,6(1h,5h)-dione
CHEBI:9536 ,
SPECTRUM_001812
IDI1_000990
D06106
SPECTRUM5_001901
thiamylal
C07846
5-allyl-5-(1-methylbutyl)-2-thiobarbituric acid
77-27-0
DB01154
barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio- (van)
einecs 201-018-3
dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6-(1h,5h)-pyrimidinedione
nsc 120815
5-allyl-5-(1-methylbutyl)-2-thiobarbitursaeure
KBIOGR_001014
KBIO2_004873
KBIO3_002805
KBIOSS_002307
KBIO2_007441
KBIO2_002305
SPECTRUM2_000384
SPBIO_000567
NINDS_000990
SPECTRUM3_001782
SPECTRUM4_000577
BSPBIO_003303
CHEMBL440
5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione
thiamylal [usp]
01t23w89fr ,
unii-01t23w89fr
thiamylal [who-dd]
thiamylal [mi]
thiamylal [vandf]
4,6-dihydroxy-5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2,5-dihydropyrimidine-2-thione
gtpl7305
SCHEMBL548050
SCHEMBL12998413
DTXSID3048441
5-allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1h,5h)-pyrimidinedione #
XLOMZPUITCYLMJ-UHFFFAOYSA-N
5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione
HY-A0218
CS-6709
thiamylal, analytical standard
5-allyl-5-(pentan-2-yl)-2-thioxodihydropyrimidine-4,6(1h,5h)-dione
Q906102
BRD-A23970436-236-03-4

Research Excerpts

Overview

Thiamylal is an ultrashort-acting barbiturate used for intravenous administration or general anesthesia induction.

ExcerptReferenceRelevance
"Thiamylal is an ultrashort-acting barbiturate used for intravenous administration or general anesthesia induction. "( Quantitative analysis of thiamylal and its metabolite secobarbital using liquid chromatography-tandem mass spectrometry in adipose tissue, serum, and liver.
Asano, M; Kondo, T; Kuse, A; Morichika, M; Nakagawa, K; Sakurada, M; Takahashi, M; Ueno, Y; Yoshioka, N, 2022
)
2.47

Toxicity

The primary endpoint was the success rate of MRI. Secondary endpoints were adverse events related to sedation, time to sedate, recovery time, and the dose of thiamylal.

ExcerptReferenceRelevance
"We studied the efficacy and adverse effects of rectal thiamylal in combination with oral triclofos in sedation for pediatric magnetic resonance imaging."( Efficacy and adverse effects of rectal thiamylal with oral triclofos for children undergoing magnetic resonance imaging.
Itomi, K; Iwata, S; Kato, T; Kuno, K; Okumura, A, 2006
)
0.85
" The primary endpoint was the success rate of MRI, while secondary endpoints were adverse events related to sedation, time to sedate, recovery time, and the dose of thiamylal."( Efficacy and safety of intravenous thiamylal in pediatric procedural sedation for magnetic resonance imaging.
Hirai, K; Irie, S; Kano, K; Migita, M; Yanabe, S, 2020
)
1.03
" Our novel "step-down infusion" method under normothermia enabled to maintain stable, safe thiamylal concentrations to ensure both ICP reduction and CPP maintenance without any serious side effects, may provide a novel and clinically effective treatment option for patients with increased ICP."( A novel step-down infusion method of barbiturate therapy: Its safety and effectiveness for intracranial pressure control.
Jono, H; Morioka, M; Nakamura, Y; Negoto, T; Oda, K; Orito, K; Saito, H; Takeshige, N; Takeuchi, Y; Yamakawa, Y; Yamamoto, M; Yoshitomi, M, 2021
)
0.84

Pharmacokinetics

The pharmacokinetic behavior of thiamylal enantiomers was studied in patients undergoing thiamylamine treatment. Disposition of the enantiomer best conformed to 2 multicompartmental models.

ExcerptReferenceRelevance
" Using a two-compartment pharmacokinetic model, disposition kinetics were studied."( Pharmacokinetics of intravenous procaine infusion in humans.
Chapman, J; Ferrari, AA; Seifen, AB; Seifen, EE; Thompson, DS,
)
0.13
" Disposition of thiamylal best conformed to 2 multicompartmental models, a 2-compartment (n = 1) and a 3-compartment (n = 5) open pharmacokinetic model."( Pharmacokinetics of thiamylal in cats.
Benson, GJ; Davis, LE; Koritz, GD; Thurmon, JC; Tranquilli, WJ; Wertz, EM, 1988
)
0.94
" The pharmacokinetic behavior of thiamylal enantiomers was studied in patients undergoing thiamylal treatment."( Pharmacokinetics of thiamylal enantiomers in humans.
Futugami, K; Ikeda, T; Kataoka, Y; Oishi, R; Sueyasu, M; Taniyama, T, 1997
)
0.9

Compound-Compound Interactions

The optimal dose range, to maintain haemodynamic stability, for thiamylal induction of anaesthesia in combination with midazolam, 0.5 mg was determined.

ExcerptReferenceRelevance
"The optimal dose range of thiamylal, combined with midazolam, in the induction of anaesthesia was evaluated using haemodynamic variables."( Optimal dose of thiamylal in combination with midazolam for induction of anaesthesia.
Hanaoka, K; Nishiyama, T, 1996
)
0.94

Dosage Studied

The cardiorespiratory effects of thiamylal (10 mg/kg of body weight, IV) and the effects of preanesthetic medication with diazepam, acepromazine, detomidine, or xylazine were evaluated in 6 adult horses. We conclude that epinephrine, dopamine, and dobutamine are capable of producing cardiac arrhythmias in vagotomized and nonvagotomized thiamyllal-halothane anesthetized dogs.

ExcerptRelevanceReference
" Group B (n = 10), H24 (n = 5), and H72 (n = 5) were anesthetized with sodium thiamylal (B) or halothane and N2O (H24, H72) for 3 h, during which a dose-response curve to histamine was obtained."( Prolonged hyporesponsiveness of airway smooth muscle to histamine following general anesthesia.
Amyot, R; Chapleau, D; Couture, J; Michoud, MC; St-Jean, S, 1986
)
0.5
" We conclude that epinephrine, dopamine, and dobutamine are capable of producing cardiac arrhythmias in vagotomized and nonvagotomized thiamylal-halothane anesthetized dogs and that bilateral vagotomy decreases the dosage of epinephrine, dopamine, and dobutamine required to produce cardiac arrhythmias."( Arrhythmogenicity of dopamine, dobutamine, and epinephrine in thiamylal-halothane anesthetized dogs.
Bednarski, RM; Muir, WW, 1983
)
0.71
"The cardiorespiratory effects of thiamylal (10 mg/kg of body weight, IV) and the effects of preanesthetic medication with diazepam, acepromazine, detomidine, or xylazine administered prior to a thiamylal dosage of 6 mg/kg, IV, were evaluated in 6 adult horses."( Effects of diazepam, acepromazine, detomidine, and xylazine on thiamylal anesthesia in horses.
Mason, DE; Muir, WW, 1993
)
0.81
" Dosage below 25 mg."( A barbiturate antidote. Use of methylethyl-glutarmide in barbiturate intoxication and in terminating barbiturate anesthesia.
MARMER, MJ, 1959
)
0.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
organosulfur compoundAn organosulfur compound is a compound containing at least one carbon-sulfur bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID167610Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1130943Octanol-water partition coefficient, log P of nonionized form of compound1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID1130940Retention index of the compound by HPLC method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID1130944Hypnotic activity in rabbit1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID26581pKa value of the compound;ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID169098Negative log of molar concentration (-log C) required to produce 50% inhibition of oxygen (oxygen uptake) on rat brain respiration in vitro; ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID38915Negative log of molar concentration (-log ED50) required to reduce cell division by 50% in Arbacia egg; ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (420)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990274 (65.24)18.7374
1990's86 (20.48)18.2507
2000's37 (8.81)29.6817
2010's15 (3.57)24.3611
2020's8 (1.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.75 (24.57)
Research Supply Index6.22 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials40 (8.64%)5.53%
Reviews6 (1.30%)6.00%
Case Studies46 (9.94%)4.05%
Observational1 (0.22%)0.25%
Other370 (79.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]